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We report here investigation into the genetic basis of mouse hepatitis virus strain 1 (MHV-1) pneumoviru-
lence. Sequencing of the 3 one-third of the MHV-1 genome demonstrated that the genetic organization of
MHV-1 was similar to that of other strains of MHV. The hemagglutinin esterase (HE) protein was truncated,
and reverse transcription-PCR (RT-PCR) studies confirmed previous work that suggested that the MHV-1 HE
is a pseudogene. Targeted recombination was used to select chimeric viruses containing either the MHV-1 S
gene or genes encoding all of the MHV-1 structural proteins, on an MHV-A59 background. Challenge studies
in mice demonstrated that expression of the MHV-1 S gene within the MHV-A59 background (rA59/SMHV-1)
increased the pneumovirulence of MHV-A59, and mice infected with this recombinant virus developed pul-
monary lesions that were similar to those observed with MHV-1, although rA59/SMHV-1 was significantly less
virulent. Chimeras containing all of the MHV-1 structural genes on an MHV-A59 background were able to
reproduce the severe acute respiratory syndrome (SARS)-like pathology observed with MHV-1 and reproduc-
ibly increased pneumovirulence relative to rA59/SMHV-1, but were still much less virulent than MHV-1. These
data suggest that important determinants of pneumopathogenicity are contained within the 3 one-third of the
MHV-1 genome, but additional important virulence factors must be encoded in the genome upstream of the S
gene. The severity of the pulmonary lesions observed correlates better with elevated levels of inflammatory
cytokines than with viral replication in the lungs, suggesting that pulmonary disease has an important
immunological component.
Severe acute respiratory syndrome (SARS) is an infectious
disorder that was first diagnosed in China in November 2002
and subsequently spread worldwide (22, 46, 55). SARS was
documented in over 8,000 persons, with 778 deaths (55) before
the outbreak was extinguished. Electron microscopy, virus iso-
lation, cloning, and sequencing studies demonstrated that a
novel coronavirus (SARS-CoV) was the etiologic agent of
SARS (10, 19, 26, 35, 41). Shortly thereafter, the coronavirus
etiology of SARS was confirmed when Koch’s postulates were
fulfilled using cynomolgus macaques (Macaca fuscicularis)
(12). In 2003 and 2004, laboratory-associated cases in Singa-
pore, Taiwan, and Beijing were reported, as were four non-
laboratory-associated cases in Guandong Province, People’s
Republic of China (PRC) (53, 54), underlining the possibility
of reemergence of SARS.
The SARS coronavirus (SARS-CoV) represents a zoonotic
outbreak likely transmitted to humans from palm civets and rac-
coon dogs in wild animal markets, although these animals do not
appear to be the natural host for the virus (15). Recently, SARS-
like coronaviruses were identified in Chinese horseshoe bats,
making these animals the likely animal reservoir of the SARS-
CoV (21, 24). Phylogenetic analyses place the SARS-CoV in
group 2b, an early branch of the group 2 coronaviruses.
The group 2 coronaviruses also contain the mouse hepatitis
viruses (MHVs) (44), a group of viruses that have been studied
extensively in rodent models of human diseases (50). A num-
ber of diseases are produced by different strains of MHV, and
the disease produced is also somewhat dependent upon the
route of inoculation and the age and strain of the recipient
mouse. Strain MHV-JHM (also called MHV-4) is strongly
neurotropic, produces minimal hepatic lesions, and is poorly
pneumotropic. MHV-A59 is neurotropic and hepatotropic,
and MHV-3 and MHV-2 are strongly hepatotropic. Studies of
MHV-JHM, MHV-A59, and MHV-2 utilizing targeted recombi-
nation to create chimeric viruses have demonstrated that the viral
spike (S) protein has a major effect on pathogenesis and tropism
(7, 27, 28, 37, 39). This is not surprising since the S protein
recognizes CEACAM-1, the cellular receptor for MHV, on the
plasma membrane and mediates virus entry into the cell as well as
cell-to-cell spread during infection (51). Other MHV genes influ-
ence pathogenesis as well (6, 16, 28, 29, 31, 45).
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Recently we identified a strain of MHV, MHV-1, that is
highly pneumotropic, produces high mortality, and reproduces
most of the pathological features of SARS after intranasal
challenge of A/J mice (9). In this work, we began to examine
the genetic basis for MHV-1 pneumotropism and pneumoviru-
lence. Sequencing of the 3 one-third of the MHV-1 genome
coding for the structural proteins demonstrated that the ge-
netic organization of MHV-1 was generally similar to that of
other strains of MHV. The open reading frame (ORF) encod-
ing the hemagglutinin esterase (HE) protein is truncated, and
subgenomic mRNA 2b is not transcribed; thus, the HE gene is
a pseudogene. Chimeric viruses containing either the MHV-1
S gene or genes encoding all of the MHV-1 structural proteins,
on MHV-A59 and MHV-JHM backgrounds, were generated
by targeted recombination. Challenge studies with mice dem-
onstrated that the MHV-1 S gene conferred pneumotropism
and a low degree of pneumovirulence in an MHV-A59 back-
ground, but not in an MHV-JHM background. Infections with
chimeric viruses containing all of the MHV-1 structural genes
in an MHV-A59 background reproduced the SARS-like pa-
thology observed with MHV-1 and increased pneumovirulence
relative to the MHV-A59/MHV-1-S chimeric virus, but were
still considerably less virulent than MHV-1. These data suggest
that important determinants of pneumopathogenicity are con-
tained within the 3 one-third of the MHV-1 genome, but
additional virulence factors must lie upstream of the S gene.
MATERIALS AND METHODS
Cells and virus. DBT and 17Cl-1 were maintained at 37°C and 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% calf
serum (HyClone, Logan, UT). FCWF (Felis catus whole fetus) cells were grown
in DMEM supplemented with 10% fetal bovine serum. L2 cells were maintained
at 37°C and 3% CO2 in DMEM supplemented with 10% calf serum. The origin
and growth of the MHV-1 (9), recombinant MHV-A59 (rA59) (38), recombinant
MHV-JHM (rJHM) (29), MHV-3 (23), and MHV-S (9) viruses used in this study
have been described previously. The rJHM strain used here is derived from the
highly neurovirulent strain JHM.SD (originally called MHV-4) (32). Recombi-
nant feline A549 (fA59) (20) and feline JHM (fJHM) (33) viruses contained the
feline infectious peritonitis virus (FIPV) spike protein ectodomain in place of the
MHV-A59 and MHV-JHM ectodomains and were propagated in FCWF cells.
Sequencing of MHV-1. Total RNA was extracted from MHV-1-infected 17Cl-1
cells using an RNeasy minikit (Qiagen), and cDNAs were synthesized with
reverse transcriptase (Superscript II; Invitrogen). Overlapping cDNAs were am-
plified by PCR using primers based on the MHV-1 HE pseudogene (GenBank
accession no. M64313), a partial S gene (GenBank accession no. D8333), and the
N gene (GenBank accession no. M35253) sequences present in the public data-
bases and a mixture of Vent and recombinant Tth-XL (rTth) DNA polymerases
(30). The resulting amplified cDNAs were purified by gel electrophoresis and
subjected to automated sequencing without cloning. The complete list of oligo-
nucleotides used for reverse transcription-PCR (RT-PCR) and sequencing can
be obtained by contacting the authors.
Generation and amplification of MHV-1 cDNA clones. DBT cells were in-
fected with MHV-1 at a multiplicity of 0.3, and total RNA was extracted at 7 h
postinfection using an RNEasy minikit. The freshly prepared RNA was used as
a template for cDNA synthesis (Superscript II; Invitrogen) with primers specific
to regions containing the structural genes. For the region encompassing the HE
gene from codon 28 extending into the E gene, cDNA was primed with an
oligonucleotide designated E60-40rev with the sequence GACTATAAAAATA
ATCTGCC. The resulting cDNA was PCR amplified with the forward primer
HE28-BsmBI-FW-new (sequence GTACGTCTCAACCTCTCAACATCGTTT
CAC), containing a BsmBI site at its 5 end to facilitate later recombinant DNA
manipulations not described in this work, and the reverse primer E60-40Rev,
using a mixture of Vent and rTth DNA polymerases as described previously (30).
The resulting amplicon, designated HE-S, was TA cloned into pGEM-T Easy
(Promega). Similarly, a cDNA that would encompass the 3 end of the genome
was synthesized by reverse transcription-PCR (RT-PCR) using primer N-RV-
SfiI [GGCCATTTAGGCCTTAATTAA(T)15GTGATTCTTCAATTGGCC]
for the cDNA synthesis reaction and amplified with S45-FW5 (GCGATTGGT
GCTATACAGG, nucleotides [nt] 4109 to 4128 in GenBank accesssion no.
EF682498) and N-RV-SfiI primers for the PCR step. The amplified DNA frag-
ment extending from nucleotide 4109 to the 3 poly(A) tail in GenBank accession
no. EF682498 was subsequently TA cloned into pGEM-T Easy, and two clones,
designated SN#4 and SN#13, were obtained. A cDNA extending from positions
1379 to 5477 and containing the S gene from codon 9 was similarly RT-PCR
amplified with forward primer CCTAATACCCTCTTGCCTAGGGTATATTG
GTGACTT and reverse primer CTGTCCTTCCACCTGCAGGTGTACATCT
AGTCAATCCTCG. To allow subsequent recombinant DNA manipulations, the
forward primer contained two coding silent mutations in codons 13 and 14 of the
spike gene (T1394C and T1395C relative to GenBank accesssion no. EF682498)
to introduce an AvrII site (underlined in the primer sequence). The reverse
primer introduced mutations G5458C, C5460T, T5461G, T5463A, C5464G, and
C5465G (all mutations are in the positive sense) to introduce the SbfI site
(underlined in the primer sequence) 3 to the spike gene termination codon and
prior to the gene 4 transcriptional regulatory sequence. The resultant cDNA
fragment was TA cloned into PCR 2.1 Topo and designated clone 4B. All clones
were sequenced in their entirety.
Plasmid constructions. All positions for oligonucleotides or mutagenesis are
given relative to GenBank accesssion no. EF682498. The MHV-1 spike gene 4B
clone contained an AvrII site at positions 4734 to 4739, in addition to the AvrII
site engineered into the 5 end of the clone by RT-PCR. The internal AvrII site
at 4734 to 4739 was removed without introducing a coding change by PCR-
mediated mutagenesis (mutations T4736A and G4739A), to produce cDNA
clone 4B1. This allowed the subsequent use of the AvrII and SbfI sites that were
introduced into the 5 and 3 ends of this clone during RT-PCR cloning (see
above), to transfer the MHV-1 spike gene to the targeted recombination plas-
mids pMH54 (for MHV-A59) (20) and pJHM (for MHV-JHM) (33), to produce
plasmids pMH54/SMHV-1 and pJHM/SMHV-1, which were used in the targeted
recombination studies described below. Additionally, site-directed mutagenesis
was used to introduce two additional coding silent mutations into clone 4B1
(T2384A and G2552A) to destroy two BsmBI sites that would interfere with
subsequent recombinant DNA manipulations not described here. The resultant
plasmid was designated 4B1BsmBI.
A cDNA clone extending from codon 28 of the HE gene into the E gene,
designated clone HE-S#3, underwent site-directed mutagenesis to insert an
AvrII site at nucleotides 1394 to 1399 (T1394C and T1395C). This was accom-
plished by site-directed mutagenesis of a subcloned AgeI-StuI fragment followed
by restriction fragment exchange to introduce the AvrII site into HE-S#3 to
produce cDNA clone HE-S-AvrII. Clone SN#13, a cDNA clone extending from
position 4109 into the poly(A) tail followed by PacI and SfiI sites, was subjected
to site-directed mutagenesis to insert an SbfI site at nucleotides 5459 to 5466, just
downstream of the S gene stop codon. Site-directed mutagenesis was performed
by PCR amplification of a fragment containing nucleotides 5453 to 6047 using
clone SN#13 as template, a mutagenic forward primer (TGTACACCTGCAG
GGGAAGGACAGAAAATCTAAAC; the introduced SbfI site is underlined,
and a naturally occurring BsrGI site is double underlined), and a reverse primer
containing an AvaI restriction site [CTCGGGGTTGGCAAT; the AvaI site is
underlined]) followed by TA cloning. The introduced SbfI site was then shuttled
back into clone SN#13 by restriction fragment exchange using an AvaI site at
positions 6042 to 6047 and a BsrGI site (nt 5453 to 5458) immediately 5 to the
introduced SbfI site. SN#13 then underwent an additional restriction fragment
exchange with its sibling clone SN#4 to eliminate two mutations in the N gene
to produce a clone, designated SNF2. Clones HE-S-AvrII and SNF2 were ligated
together utilizing a shared unique BglII site (nucleotides 4240 to 4205) and a 3
flanking SalI site in pGEM-T Easy to produce the plasmid pHe-N, a construct
that containing the HE gene from codon 28 to the poly(A) tail. The introduced
AvrII and SbfI sites were then used to replace the majority of the S coding
sequences with those in clone 4B1BsmBI to correct errors that were introduced
into the S gene during RT-PCR-based cloning and to facilitate future recombi-
nant DNA manipulations at the 5 end of the construct that will utilize the
BsmBI site at the 5 end of the construct using “no see’m technology” (58). This
clone, designated pMHV-1BsmBI, corresponded to the wild-type sequence
from HE codon 28 through the 3 end, with the exception of the noncoding
changes in the S gene described above, a coding silent T6404C change in the E
gene, a T6032C mutation in gene 5a that changes a tyrosine to a histidine in the
gene 5a protein, and an extra G which was inadvertently inserted after the SbfI
site located in a noncoding region between the S and open reading frame 4
(ORF4) genes.
The MHV-1 sequences downstream of S extending to the 3 end of the
genome were excised from pHe-N using SfbI and PacI and were placed into
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pMH54/SMHV-1 and pJHM/SMHV-1 by restriction fragment exchange to produce
the plasmids pMH54/S-3UTRMHV-1 and pJHM/S-3UTRMHV-1, respectively.
These plasmids were subsequently used in targeted recombination studies de-
scribed below.
Targeted recombination. After digestion with PacI to linearize the plasmids,
donor RNAs were transcribed with T7 RNA polymerase as previously described
from plasmids pMH54/SMHV-1 and pMH54/S-3UTRMHV-1 for isolation of
MHV-A59/MHV-1 recombinant viruses and from pJHM/SMHV-1 and pJHM/
S-3UTRMHV-1 for isolation of MHV-JHM/MHV-1 recombinant viruses (20, 33).
Targeted recombination with MHV-A59 and MHV-JHM was performed as
previously described (20, 33). Briefly, two viruses, fMHV (20), corresponding to
MHV-A59, in which the sequences encoding the spike protein ectodomain had
been replaced by the corresponding feline infectious peritonitis virus (FIPV)
spike ectodomain coding sequences, and fJHM (20, 33), in which the MHV-JHM
spike ectodomain coding sequence had similarly been replaced by the FIPV
ectodomain sequences, were used as acceptor viruses. FCWF cells were infected
with either fMHV or fJHM and incubated for 4 h. Cells were then electroporated
with donor RNAs with two pulses of 300 V and 960 F and overlaid onto
monolayers of 17CL-1 cells. The cultures were incubated for up to 72 h or until
cytopathic effect destroyed the 17CL-1 monolayer. Recombinant viruses able to
enter and replicate in murine cells, and thus which contained the MHV-1 spike
ectodomain, were selected by plaquing on L2 cells. Plaques containing putative
recombinant viruses were picked and underwent a second cycle of plaque puri-
fication. The viruses twice plaque cloned were expanded in murine cells, and
their recombinant nature was confirmed by sequencing.
RNA analyses. For metabolic labeling studies, replicate cultures of DBT cells
in 12-well plates were infected with MHV at a multiplicity of infection (MOI) of
1, or mock infected, and incubated for 6 h. Cultures were then washed twice with
phosphate-free DMEM and fed with DMEM containing 2% dialyzed calf serum
and 10 g/ml actinomycin D. After 15 min of incubation at 37°C, cells were
labeled by replacing the medium with fresh phosphate-free DMEM containing
10 g/ml actinomycin D, 2% dialyzed serum, and 200 Ci/ml 32PO4 and incu-
bated for an additional 5.5 h. The labeled cultures were washed twice with cold
phosphate-buffered saline (PBS), and RNA was extracted using an RNeasy
minikit. Ten micrograms of RNA was electrophoresed in a 1% formaldehyde–
agarose gel at 100 V for 5 h. Following electrophoresis, the gel was soaked in
70% methanol for 30 min, dried, and exposed to X-ray film.
RT-PCR analysis was performed on RNA extracted from cells infected with
MHV at 7 h postinfection. cDNA synthesis was primed with an antisense oligo-
nucleotide corresponding to positions 420 to 402 of the HE gene (CAAAGGA
TAGGCTCCTATA). Forty cycles of PCR amplification was carried out with a
sense primer corresponding to nucleotides 1 to 23 of the MHV leader sequence
(GTATAAGAGTGATTGGCGTCCGT) and the same antisense primer used
for cDNA synthesis. Amplified DNA fragments were displayed by agarose gel
electrophoresis.
Cytokine and chemokine analyses. Relative amounts of mRNA encoding macro-
phage colony-stimulating factor (M-CSF), fibrinogen-like protein 2 (FGL2), tumor
necrosis factor alpha (TNF-), alpha 1 interferon (IFN-1), IFN-2, IFN-4,
IFN-5, IFN-, IFN-, interleukin-6 (IL-6), chemokine (C-C motif) ligand 2
(CCL2), CCL3, CCL5, and chemokine (C-X-C motif) ligand 2 (CXCL2) were
determined using the GeXP genetics analysis system (Beckman Coulter, Inc.,
Fullerton, CA). Total RNA was extracted from lung tissue using the RNeasy
minikit following the manufacturer’s protocol. Primers for multiplex RT-PCR
were designed using the primer design module of the GeXP Express Profiler
software system (Beckman Coulter). The 5 end of each reverse primer was
designed to contain the 19-nucleotide universal tag sequence 5-GTACGACTC
ACTATAGGGA-3. Similarly, the 5 end of each forward primer was designed
to contain the 18-nucleotide universal tag sequence 5-AGGTGACACTATAG
AATA-3. Primer pairs were designed to yield products ranging from 142 bp to
330 bp, with a spacing of at least 5 nucleotides. The reverse primer mix contained
500 nmol/liter of each reverse primer. The forward primer mix contained 200
nmol/liter of each forward primer. cDNAs were synthesized in a reaction mixture
containing 1 l of total RNA, 3 l of nuclease-free water, 4 l of 5 reverse
transcriptase buffer (Beckman Coulter, Inc., Fullerton, CA), 2 l of the reverse
primer mix, and 1 l of Moloney murine leukemia virus reverse transcriptase
(Beckman Coulter). The reverse transcription reaction mixtures were incubated
for 1 min at 48°C, 5 min at 37°C, and 60 min at 42°C and finally for 5 min at 95°C.
Multiplex PCRs were assembled as follows: 9.3 l reverse transcription reaction
mixture, 4 l 5 PCR buffer (Beckman Coulter), 2 l forward primer mix, 4 l
of 25 mM MgCl2 and 0.7 l Thermo-Start DNA polymerase (Thermo Scientific).
Thirty-five cycles of PCR amplification were performed using the following
conditions: 10 min at 95°C, 30 s at 94°C, 30 s at 55°C, and 1 min at 68°C. All PCRs
were performed in duplicate. The multiplex PCR products were analyzed by
capillary electrophoresis on a GeXP genetic analysis system (Beckman Coulter).
Data analysis was conducted using the eXpress Analysis module of the GeXP
Express Profiler software system (Beckman Coulter). Relative gene expression in
each sample was compared by normalizing it against a housekeeping gene (cod-
ing for GAPDH [glyceraldehyde-3-phosphate dehydrogenase]). Data are pre-
sented as changes in expression relative to the untreated control samples 
standard error (n 	 3 for each cytokine and time point).
Serum cytokine levels (IL-6, IL-10, CCL2 [monocyte chemoattractant protein
1; MCP-1], IFN-, TNF-, and IL-12 p70) were assayed using the Cytometrix
bead array kit for inflammation (BD Biosciences Mississauga, ON, Canada)
as previously described (9). Serum samples were processed as per the man-
ufacturer’s instructions and analyzed using a Becton Dickinson FACScan flow
cytometer.
Mice. Female A/J mice 6 to 8 weeks of age (Charles River Laboratories and
Jackson Laboratories) were maintained in microisolator cages and fed standard
lab chow diet and water ad libitum. Viral infections were performed in a viral
isolation room as previously described (9). Briefly, mice were anesthetized by
intraperitoneal injection with pentobarbital diluted in normal saline, 50 l of
virus diluted in ice-cold DMEM was instilled into the nares, and mice were
observed until the virus was inhaled. Mice were monitored daily for symptoms of
disease, including ruffled fur, tremors, respiratory distress, and lack of activity.
Mice having any combination of three of these clinical signs were considered to
be in extremis and were euthanized. At various times postinfection, mice were
sacrificed by lethal pentobarbital anesthesia. Lungs, livers, brains, and spleens
were collected and analyzed for viral titers and histology as previously described
(9). Viral titers were determined by plaque assay on monolayers of L2 cells as
previously described. All protocols were approved by Animal Welfare Commit-
tees and complied with NIH and CIHR guidelines.
Histology. Tissue samples were formalin fixed, embedded in paraffin, sec-
tioned, stained with hematoxylin and eosin, and read by a board-certified pa-
thologist (M.J.P.) who was blinded to the clinical aspects of the study. Sections
of the lung from all groups and controls were examined by light microscopy.
Assessment of the degree of lung pathology was made. Since the main pathology
was interstitial pneumonitis with reduction in pulmonary open alveolar air
spaces, a scoring scheme based on estimated airway space visualized was used as
follows: fully expanded airways, normal (N); 0 to 30% reduction in airway space,
mild lung disease (
); 31 to 60% reduction in airway space, moderate lung
disease (

); 61 to 90% reduction in airways, severe lung disease (


); and
91 to 100% reduction, severe lung disease with consolidation (



).
Statistics. Viral titers were analyzed by analysis of variance (ANOVA) to
determine if replication of the recombinant viruses was different from that of
parental MHV-1. A P value of 0.05 was considered statistically significant.
RESULTS
Sequence analysis and molecular cloning of the MHV-1
structural gene region. As a first step in performing reverse
genetics studies to investigate the basis of MHV-1 pneumo-
virulence, we determined the sequence of 8,905 nucleotides of
the MHV-1 genome extending from the first nucleotide of the
HE pseudogene to the poly(A) tail (GenBank accession no.
EF682498). This region includes all of the MHV structural
proteins as well as genes 4 and 5a, which encode nonstructural
proteins. Analysis of the open reading frames present indicates
the genetic structure of MHV-1 is similar to those of other
MHV strains (Fig. 1A). There are several notable features. As
reported previously (57), the HE gene was a pseuodgene (see
below) containing an open reading frame truncated to 268
amino acids as compared to 440 amino acids in the intact and
functional MHV-JHM HE gene. Gene 4 contained a single
139-amino-acid open reading frame like MHV-JHM, rather
than the two smaller open reading frames found in MHV-A59.
The S gene encoded a protein of 1,363 amino acids generally
similar to other MHV S proteins that have been sequenced.
The sequence at the MHV-1 S1-S2 cleavage site, TSHRARRS,
differed only slightly from the KSRRARRS and KSRRAHRS
cleavage sites (cleavage is between the underlined residues)
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found in MHV-JHM (43) and MHV-A59 S proteins (25),
respectively, suggesting that the MHV-1 spike protein will be
cleaved as are those of MHV-JHM and MHV-A59. Cell-cell
fusion was observed in MHV-1-infected cell cultures, consis-
tent with the presence of a putative cleavage site in MHV-1 S.
The MHV-1 S protein has four small deletions of four, four,
three, and two amino acids relative to the MHV-JHM S pro-
tein, the longest S protein reported. These deletions are all
outside of the receptor binding domain, residues 1 to 330.
However, the two four-amino-acid deletions in MHV-1 ablate
the C57BL/6 immunodominant cytotoxic T-lymphocyte (CTL)
epitope (CSLWNGPHL; S-510-518) (3) that is present in the
MHV-JHM S protein. The MHV-JHM subdominant epitope
(RCQIFANI; S-598-605) (3) is not conserved in MHV-1; the
corresponding sequence is rather RCHIFSNL. However, this
sequence contains the anchor residues needed for major his-
tocompatibility complex (MHC) binding and is predicted to be
a C57BL/6 (H-2b) CTL epitope by the Promiscuous MHC
Class-I Binding Peptide Prediction Server (http://www.imtech
.res.in/raghava/propred1/). Alignment of the MHV-1, MHV-
JHM, MHV-A59, and MHV-2 S proteins by ClustalW and
calculation of a distance matrix indicate the MHV-1 S protein
sequence is somewhat more similar to the MHV-2 S protein
than to either the MHV-JHM or MHV-A59 S proteins.
The MHV-1 HE gene is a pseudogene. It has been reported
previously that a subgenomic mRNA containing the HE gene
cannot be detected in metabolic labeling studies of MHV-1-
infected cells (57). In light of the fact that the transcriptional
regulatory sequences (TRSs) immediately upstream of the
MHV-JHM and MHV-S and MHV-1 HE coding sequences
are identical (57), we reexamined this question. Metabolic
labeling of MHV-1-infected cells with 32Pi failed to demon-
strate the presence of mRNA 2–1 (not shown). Furthermore,
the HE gene encoding mRNA 2–1 was not detected in MHV-
1-infected cells by a more sensitive RT-PCR assay that em-
ployed leader- and HE-specific primers, although the presence
of the HE gene encoding mRNA 2–1 was easily demonstrated
in MHV-S- and MHV-3-infected cells (Fig. 1B). As expected,
cells infected with MHV-A59, a strain reported not to express
mRNA 2–1 or the HE protein, did not give rise to a PCR
product. Thus, we concluded that an mRNA expressing the
predicted truncated version of the HE protein is not detectable
in MHV-1-infected cells.
Isolation and in vitro characterization of rA59/MHV-1 re-
combinant viruses. Previous studies have shown that in the
context of A59/JHM chimeric viruses, the S gene plays a major
role in tropism and virulence (7, 27, 37, 39). Further work with
additional A59/JHM chimeras has demonstrated that other
structural genes, in addition to the S gene, but not the replicase
gene, are major determinants of tropism and level of virulence
(14, 28, 29). Thus, we isolated recombinant MHV-A59 viruses
in which the A59 S gene was replaced by MHV-1 S (designated
rA59/SMHV-1) (Fig. 2A) by targeted recombination (20), and a
second set of recombinants in which the A59 sequences from S
through the 3 end of the genome were replaced by their
MHV-1 counterparts (designated rA59/S33UTRMHV-1)
(Fig. 2A). The genomes of these recombinant viruses were
partially sequenced to verify their genetic structure. To ensure
that these recombinant viruses replicated comparably to the
parental viruses in cell culture, a growth curve experiment
comparing the growth rates of rA59, MHV-1, rA59/SMHV-1,
and rA59/S33UTRMHV-1 in L2 cells was performed (Fig.
2B). All viruses replicated with similar kinetics, and the viruses
containing all of the MHV-1 structural genes, MHV-1 and
rA59/S33UTRMHV-1, reached virtually identical titers. rA59/
SMHV-1, a virus that contained A59 structural genes, with the
exception of the MHV-1 S gene, reached a higher titer than
those of MHV-1 and the rA59/S33UTRMHV-1 recombinant,
a titer that was only slightly less than that achieved by rA59.
We concluded that there were no obvious incompatibilities
between the MHV-1 and MHV-A59 structural genes and that
the rA59/SMHV-1 and rA59/S33UTRMHV-1 viruses were suit-
able for further in vivo studies.
MHV-S protein confers increased pneumovirulence on
MHV-A59 recombinant viruses. We examined the ability of the
parental MHV-1 and chimeric recombinant viruses for their
effect on survival and to produce pulmonary disease in A/J
mice. Previously we and others have reported that intranansal
infection of A/J mice with MHV-1 produces a lethal pulmo-
nary disease with pathological characteristics similar to that
seen in humans with SARS (9, 18). In a preliminary experi-
ment, we infected groups of MHV-1-susceptible A/J mice in-
FIG. 1. The MHV-1 HE gene is not expressed. (A) The genetic
organization of the 3 8,905 nucleotides of the MHV-1 genome. The
vertical lollipops represent the TRS sequences, including the nonfunc-
tioning TRS (gray lollipop) for the truncated HE open reading frame.
(B) RT-PCR analysis of MHV-1-infected cell RNA. Replicate cultures
were infected with MHV-S, MHV-1, MHV-3, and MHV-A59, and
RNA was extracted at 7 h postinfection. cDNA synthesis was primed
with an antisense oligonucleotide corresponding to positions 420 to
402 of the HE gene. PCR was carried out with a sense primer corre-
sponding to nucleotides 1 to 23 of the MHV leader sequence and the
same antisense primer used for cDNA synthesis. Amplification was for
25 cycles at 95°C for 15 s, 48°C for 45 s, and 72°C for 50 s followed by
a 5-min final elongation step at 72°C. The PCR products were then
resolved by agarose gel electrophoresis. The position of the 492-nu-
cleotide HE mRNA amplicon is indicated by the arrow.
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tranasally with 5,000 PFU of either MHV-1 (10 50% lethal
doses [LD50]), the isogenic control parental virus rA59, or
recombinant viruses expressing the MHV-1 S gene in an
MHV-A59 background (rA59/SMHV-1). Two independent re-
combinants were tested for rA59/SMHV-1, and identical results
were obtained with each recombinant. Mice were observed
clinically, and some mice were sacrificed for histopathologic
analysis. As expected, all mice infected with MHV-1 developed
severe respiratory symptoms (obviously increased respiratory
rate), ruffled fur, and decreased activity and were euthanized.
Histopathologic examination of the lungs from these mice re-
vealed a severe pneumonitis resembling that observed in SARS
patients, as had been reported previously (9). None of the mice
infected with rA59/SMHV-1 viruses became clinically ill after
infection with this dose of virus, and the mice survived until
they were sacrificed on day 7; histopathologic examination of
the lungs from these animals revealed a mild interstitial pneu-
monitis (Fig. 3F and G). Thus, mice infected with recombinant
viruses containing the MHV-1 S gene failed to develop signif-
icant pulmonary disease at this dose of virus, indicating that at
5,000 PFU, the S gene by itself did not appear to confer
pneumovirulence on MHV-A59. Virus titers of lung homoge-
nates of mice infected with rA59/SMHV-1 demonstrated that
the chimeric virus replicated in the lung, achieving a mean
peak titer of 5.6  105 PFU/g at 36 h postinfection. After this
time, the titer declined to 3.5  103 by day 7.
We then infected groups of A/J mice (n 	 10 mice/group)
intranasally with 5,000 PFU of either MHV-1, with the isogenic
control parental virus rA59, or with a recombinant viruses
containing all of the MHV-1 genetic information from S to the
3 end of the genome (rA59/S33UTRMHV-1). All of the
MHV-1-infected mice developed respiratory distress and died
or were euthanized within 8 days of infection. Eight of 10
(80%) of the rA59 mice became severely ill and were eu-
thanized by day 10. All of the mice infected with rA59/
S33UTRMHV-1 recombinant viruses became severely ill,
with increased respiratory rates, ruffled fur, and decreased
activity, similar to the clinical findings observed in MHV-1-
infected mice. However, only 2 of these 10 mice became suf-
ficiently ill as to require euthanasia (Fig. 4A).
MHV-1 and rA59 replicated to high titers. Peak viral titers
of 108 and 109 PFU were seen at 36 h in lung tissue from
MHV-1 and rA59, respectively, and virus titers greater than
104 PFU were still detected even at 7 days postinfection, at
which time most animals had died or had been euthanized
(Fig. 4B). Both of the rA59/S33UTRMHV-1 recombinant vi-
ruses replicated 100-fold less in the lung, with peak titers of
4  105 to 8  105 PFU at 36 h postinfection, and by day 7,
virus was cleared from the lungs of rA59/S33UTRMHV-1-
infected mice, whereas substantial (104 to 105 PFU/g) amounts
of virus were still easily detectable in lungs of mice infected
with rA59 and MHV-1 (Fig. 4B). Replication of rA59 in the
lung was statistically greater than that of MHV-1 and all re-
combinant viruses (P  0.02). However, replication of MHV-1
was not statistically different from that of recombinant viruses
(P 	 0.996).
Histopathologic examination of the lungs from uninfected
A/J mice showed widely patent alveoli with normal architec-
ture (Fig. 3A). Lungs from A/J mice infected with MHV-1
contained a moderate interstitial pneumonitis on day 4 (Fig.
3B), which by day 7 (Fig. 3C) had progressed to severe dif-
fuse interstitial pneumonitis with consolidation and a marked
mononuclear cell infiltrate (predominately macrophages, neu-
trophils, and lymphocytes), as previously described (9). Histo-
logic examination of the lungs of mice infected with rA59
revealed mild-to-moderate interstitial pneumonitis with little
or no alveolar changes in spite of vigorous rA59 replication
(Fig. 3D and E). Lungs from mice infected with rA59/
S33UTRMHV-1 recombinant viruses contained pathological
changes similar to those observed with MHV-1, although they
FIG. 2. Replication of rA59/MHV-1 viruses in cell culture. (A) Schematic diagrams of the rA59/SMHV-1 and rA59/S33UTRMHV-1 viruses.
(B) Growth curves of rA59/MHV-1 chimeric recombinants and the parental viruses. Replicate cultures of L2 cells were infected with either
rA59/SMHV-1 (plaque isolate C), rA59/S33UTRMHV-1 (plaque isolate B), MHV-1, or rA59 at an MOI of 4, and two replicate cultures were
harvested for each virus at the indicated times. Viral titers were determined by plaque assay on L2 cells.
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were less severe (Fig. 3H and I). Histologic examination of
livers and brains of MHV-1-infected mice showed only mini-
mal hepatitis with architecture similar to that of uninfected
controls (Fig. 5A and B), whereas rA59-infected mice devel-
FIG. 3. Pulmonary histopathology in mice infected with rA59/
SMHV-1, rA59/S33UTRMHV-1, rA59, and MHV-1. Mice were infected
by intranasal inoculation with 5,000 PFU, sacrificed at 4 and 7 days
postinfection, and lungs were removed, fixed with buffered formalin,
paraffin embedded, sectioned, and stained with hematoxylin and eosin.
The sections shown in panels F and G are from a different experiment
from the other sections. (A) Lung from normal uninfected animal.
This micrograph shows normal lung histology. Note patency of bron-
chus on the lower right and the well-aerated, open alveolar structure
with thin alveolar walls. This is normal murine lung histology (grade 0).
(B) MHV-1 at day 4 postinfection. The lung shows diffuse changes in
lung parenchyma. There are peribronchitis and thickening of alveolar
walls, which is the result of infiltration by mononuclear cells. This is
mild-to-moderate interstitial pneumonitis (grade 2). (C) MHV-1 at
day 7 postinfection. The lung shows severe changes with near total loss
of alveolar spaces by heavy inflammatory mononuclear cell infiltrate of
alveolar walls. Note that almost the entire lung appears totally oblit-
erated. This is severe interstitial pneumonitis with consolidation (grade
4). (D) rA59 at day 4 postinfection. This lung shows patent alveoli, but
in the upper part of the micrograph, the alveolar lumens are filled with
pink-staining fluid which was seen in approximately 25% of the lung
tissue. This is normal lung, aside from areas of pulmonary edema
(grade 0). (E) rA59 at day 7 postinfection. The lung shows thickening
of alveolar walls by mononuclear cell infiltrate. Patency of airways is
significantly reduced. There was no pulmonary edema. This is moder-
ate interstitial pneumonitis (grades 2 to 3). (F) rA59/SMHV-1 at day 4
postinfection. The lung shows thickening of alveolar walls by mono-
nuclear inflammatory cells, but most airways are still patent, albeit re-
duced in size, compared to normal. There is also bronchitis. This is mild
interstitial pneumonitis (grade 1). (G) rA59/SMHV-1 at day 7 postinfection.
The lung shows thickening of alveolar walls by mononuclear cells, but
most airways are still patent, albeit reduced in size. It is essentially the
same as in day 4. This is interstitial pneumonitis (grade 1). (H) rA59/
S33UTRMHV-1 at day 4 postinfection. The lung shows peribronchitis
and scattered patches where alveolar walls are thickened by mononuclear
cells. The changes are mild. This is interstitial pneumonitis (grade 1). (I)
rA59/S33UTRMHV-1 at day 7 postinfection. The lung shows extensive
mononuclear cell infiltration of alveolar walls with great reduction in
alveolar lumens. In places, there is early consolidation of the lung paren-
chyma. This is interstitial pneumonitis (grade 3). All micrographs are
250. For panels B to I, panels on the left represent day 4, and those
on the right represent day 7.
FIG. 4. Effect of 5,000 PFU of rA59/S33UTR MHV-1 viruses on
A/J mice. Groups of 14 mice were infected intranasally with 5,000 PFU
with two independent rA59/S33UTRMHV-1 recombinants, rA59, or
MHV-1, and followed clinically as described in Materials and Meth-
ods. Mice judged to have severe disease were euthanized. (A) Survival
curve. (B) Three mice were selected randomly from each group at 36 h,
4 days, and 7 days postinfection and euthanized. Lung homogenates in
DMEM (10% [wt/vol]) were prepared, and virus titers were deter-
mined by plaque assay. Results are expressed as PFU/g of tissue. The
limit of detection was 170 PFU/g.
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oped severe widespread hepatitis with massive hepatic necrosis
(Fig. 5C) and a moderate encephalitis (data not shown) ac-
counting for the death of these animals. Only minimal liver and
brain pathology was seen in mice infected with rA59/SMHV-1
(Fig. 5D) and rA59/S33UTRMHV-1 (Fig. 5E).
To further examine the pneumovirulence of recombinant
viruses containing only the MHV-1 S gene or containing all of
the MHV-1 genetic information from S to the 3 end of the
genome, another set of A/J mice (n 	 10 mice/group) were
infected by intranasal inoculation with 100,000 PFU of rA59,
rA59/SMHV-1, or rA59/S33UTRMHV-1 recombinant viruses.
Mice were observed clinically, and some mice were sacrificed
at various times postinfection for viral titers and histopatho-
logic analysis. As shown in Fig. 6, at this higher dose of virus,
all of the rA59/S33UTRMHV-1-infected mice died, whereas
even at 100,000 PFU, only 33% of the rA59/SMHV-1-infected
mice died (Fig. 6A). At 1.5 days postinfection, the MHV-1,
rA59, rA59/SMHV-1, and rA59/S33UTRMHV-1 viruses repli-
cated to high titers in the lung (Fig. 6B), although the titer
achieved by the rA59/S33UTRMHV-1 recombinant was lower
than that achieved by the other viruses. As was the case for the
low-challenge experiment, the peak titer achieved by rA59 was
significantly (P 0.05) greater than that achieved by the rA59/
SMHV-1 and rA59/S33UTRMHV-1 recombinant viruses. By
day 4, the lung titers decreased 10- to 100-fold for all viruses
except for rA59/SMHV-1. By day 7, all of the rA59-infected mice
had died of hepatitis; pneumovirulent MHV-1 and the two
chimeric viruses persisted in the lungs. Pulmonary histopathol-
ogy of mice infected with rA59 isogenic control virus, rA59/
SMHV-1, or rA59/S33UTRMHV-1, is shown in Fig. 7. Infection
with rA59, even with an inoculum of 100,000 PFU, induced
only a mild interstitial pneumonitis without alveolar lesions in
the lung (Fig. 7A and B) in spite of the presence of high viral
titers. Infection with rA59/SMHV-1 resulted in mild interstitial
pneumonitis in the peribronchial regions by 4 days postinfec-
tion (Fig. 7C), with mild-to-moderate pneumonitis by day 7
(Fig. 7D). Consistent with its somewhat greater lethality, in-
fection with rA59/S33UTRMHV-1 produced more severe pul-
monary pathology at both day 4 and day 7 (Fig. 7E and F) than
rA59/SMHV-1, with severe interstitial pneumonitis with com-
plete consolidation of the lung seen on day 7. The changes
observed for rA59/S33UTRMHV-1 were very similar to those
seen with infection by 5,000 PFU of MHV-1. The histologic
changes observed with high doses of the two recombinant
viruses were somewhat more severe than those observed in the
prior experiments when 5,000 PFU was used as a challenge
dose. This parallels the greater lethality achieved at 100,000
PFU. A statistical analysis of pulmonary virus load in mice
infected with 100,000 PFU of chimeric and isogenic rA59 re-
combinant viruses revealed that the peak titer of rA59 in the
lung (36 h postinfection) was significantly greater than that of
the viral recombinants (P  0.05), a result similar to that
obtained with the low-dose challenge experiment (Fig. 4).
rA59 replicated to high titers in the liver (Fig. 6C), whereas
the rA59/SMHV-1 and rA59/S33UTRMHV-1 recombinants
failed to replicate well in the liver and produced no hepatopa-
thology (not shown), similar to the result obtained with the
5,000-PFU challenge (Fig. 5). Viral replication in the central
nervous system of mice infected with MHV-1, rA59/SMHV-1,
and rA59/S33UTRMHV-1 occurred later than that in mice
infected with rA59; similarly the peak titers achieved were
more than 100-fold less than those achieved with rA59 (Fig.
6D) and produced only mild histopathologic changes in the
brain (not shown).
We also isolated a parallel set of recombinants on a MHV-
JHM backbone (designated rJHM/SMHV-1 and rJHM/
S33UTRMHV-1). Both of these recombinant viruses were
completely attenuated, with no illness or death even at a chal-
lenge of 100,000 PFU. These viruses grew poorly in lung, not at
all in liver, and relatively poorly in brain. Examination of the
lungs, liver, and brain, failed to reveal any pathology in lung
and liver and found only mild encephalitic changes in brain
(not shown).
Cytokine and chemokine profiles. To examine cytokine ex-
pression in the lungs, mice were infected with 5,000 PFU of
parental rA59 and rJHM viruses; rA59/SMHV-1, rA59/
S33UTRMHV-1, rJHM/SMHV-1, or rJHM/S33UTRMHV-1
chimeras; or MHV-1. Total RNA was extracted from samples
of lung tissue harvested at 36 h, 4 days, and 7 days postinfec-
tion. Analysis for selected cytokine and chemokine mRNA
levels was performed by multiplex RT-PCR as described in
FIG. 5. Hepatic histopathology in mice infected with rA59/SMHV-1,
rA59/S33UTRMHV-1, rA59, and MHV-1. Mice were infected by in-
tranasal inoculation with 5,000 PFU and sacrificed at 7 days postin-
fection, and livers were removed, paraffin embedded, sectioned, and
stained with hematoxylin and eosin. (A) Uninfected control liver shows
normal histology. (B) MHV-1-infected liver shows minimal focal in-
flammatory cell collections in lobules and otherwise appeared normal.
(C) rA59-infected liver shows severe acute hepatic necrosis. Note large
geographic pale areas where liver cells are lost. (D) rA59/SMHV-1-
infected liver shows normal liver, aside from small, focal inflammatory
cell infiltrates in the lobular parenchyma. Note that this section is
from a separate experiment from the other panels. (E) rA59/
S33UTRMHV-1-infected liver shows normal histology. All micro-
graphs are 400.
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Materials and Methods. The results of the analysis at 36 h
postinfection are shown in Table 1. At this early time postin-
fection, cytokine and chemokine induction correlated well with
viral replication in lungs: MHV-1, rA59, rA59/SMHV-1, and
rA59/S33UTRMHV-1 generally had highly elevated (4-fold
increase relative to uninfected mice) levels of mRNA tran-
scripts for IL-6, IFN-, IFN-, IFN-2, IFN-4, and CCL2 and
more moderate (2- to 4-fold increase relative to uninfected
mice) induction of TNF-, FGL2, IFN-1, IFN-5 CCL3,
CCL5, and CXCL2. The induction of relatively high levels of
IFN-, IL-6, and CCL2 by rA59 was somewhat surprising in
light of the paucity of inflammatory changes in the lung. Vi-
ruses that replicated poorly in lung, rJHM, rJHM/SMHV-1, and
rJHM/S33UTRMHV-1, either failed to significantly (2-fold)
induce the synthesis of mRNAs for these proinflammatory
molecules or induced a moderate (2- to 4-fold) increase in a
small number of these mRNAs. The one exception to this was
rJHM/SMHV-1, which induced a 5-fold increase in IL-6.
The evolution of IFN-, TNF-, IL-6, FGL2, CCL2, and
CCL3 mRNA levels over the course of infection is shown in
Table 2. These cytokines were studied because they have been
shown to be important determinants of disease severity and
host outcome in both experimental models of SARS as well as
SARS in humans (1, 9, 49, 52). In general, a continually in-
creasing level of cytokines and chemokines after infection was
associated with more severe pulmonary pathology. IFN-,
TNF-, FGL2, and CCL3 mRNAs in lung increased continu-
ally over the course of the infection for the two viruses that
produced the most severe pulmonary disease, MHV-1 and
rA59/S33UTRMHV-1. In mice infected with rA59/SMHV-1,
pulmonary CCL3 mRNA levels also increased continuously
over the course of infection, although the levels of mRNA
observed were lower than those observed in mice infected with
MHV-1 and rA59/S33UTRMHV-1. In the same mice, CCL2
mRNA levels peaked at 4 days postinfection and declined
somewhat on day 7, and IFN- levels remained elevated but
slowly declined over the course of infection, whereas TNF-
and FGL2 were only modestly elevated and tended to decline
over time. Mice infected with rA59 had lower initial levels of
IFN-, TNF-, and FGL2 mRNAs than mice infected with
rA59/S33UTRMHV-1 or rA59/SMHV-1, and these cytokine
mRNAs tended to decline to near-normal levels over the
course of infection. IL-6 mRNA was present at high levels in
mice infected with MHV-1, and all of the viruses with an
MHV-A59 background, including rA59, but slowly declined in
all but rA59/S33UTRMHV-1, where it continued to increase
over the course of infection.
In general, mice infected with JHM or recombinant viruses
on a MHV-JHM background (viruses that replicated poorly in
lung) all had normal or only moderate induction of cytokine or
chemokine mRNAs in lung tissue relative to uninfected mice,
and these levels tended to decline over the course of infection.
FIG. 6. Effect of 100,000 PFU of rA59/SMHV-1 and rA59/S33UTRMHV-1 viruses on A/J mice. Groups of 14 mice were infected intranasally
with 5,000 PFU of MHV-1 or 100,000 PFU of rA59, rA59/SMHV-1 (plaque isolate C), or rA59/S33UTRMHV-1(plaque isolate B) and followed
clinically as described in Materials and Methods. Mice judged to have severe disease were euthanized. (A) Survival curve. (B to D) Three mice
were selected randomly from each group at 36 h, 4 days, and 7 days postinfection and euthanized. Organ homogenates in DMEM (10% [wt/vol])
were prepared, and virus titers were determined by plaque assay. Results are expressed as PFU/g of tissue. The limit of detection was 170 PFU/g.
VOL. 84, 2010 GENETIC DETERMINANTS OF MHV-1 PNEUMOVIRULENCE 9285
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
There were two notable exceptions to this: rJHMV/SMHV-1
induced a 5-fold increase in IL-6 mRNA at 36 h postinfection,
which declined over time, and rJHM/S33UTRMHV-1 induced
a modest increase in FGL2 levels starting at day 4.
Serum cytokine levels in mice infected with MHV-1, rA59/
SMHV-1, or rA59/S33UTRMHV-1 or mock infected were mea-
sured at 2 days postinfection as previously described (9). Large
increases in all cytokines tested were observed in mice infected
with the two most pneumovirulent viruses, MHV-1 and rA59/
S33UTRMHV-1 (Table 3). A much more modest (2-fold)
increase was observed in mice infected with the somewhat less
pneumovirulent rA59/SMHV-1.
In summary, these results show that elevated levels of in-
flammatory cytokine mRNAs in lung and serum cytokine levels
are sensitive correlates of disease severity, as assessed by pul-
monary pathology. The most highly pneumovirulent chimeric
virus, rA59/S33UTRMHV-1, elicited cytokine responses that
were very similar to those observed with MHV-1. The slightly
less pneumovirulent rA59/SMHV-1 elicted cytokine responses
that were somewhat more similar to those seen in rA59 than
those observed with rA59/S33UTRMHV-1, and the MHV-
JHM-based viruses, which failed to replicate well in lung, all
induced poor cytokine responses in mice.
DISCUSSION
The aim of the present study was to map the MHV deter-
minants of pneumotropism and pneumonvirulence. We report
here our initial investigations into the genetic basis of the
pneumovirulence of MHV-1 relative to other strains of MHV.
Sequencing of the 3 one-third of the MHV-1 genome contain-
ing the genes encoding the structural proteins demonstrates
that the genetic organization of MHV-1 is generally similar to
that of other strains of MHV. The open reading frame encod-
ing the hemagglutinin esterase (HE) protein is truncated, and
as demonstrated by RT-PCR, subgenomic mRNA 2b is not
transcribed, confirming earlier studies using metabolic labeling
(57) that suggested that the MHV-1 HE was a pseudogene.
Thus, it is unlikely that the HE gene contributes to MHV-1
pneumovirulence. Sequencing of the MHV-1 S gene revealed
two interesting findings: two 4-amino-acid deletions relative to
the MHV-JHM S sequence that result in the loss of the
C57BL/6 immunodominant CTL epitope CSLWNGPHL (S-
510-518) (3) contained in the MHV-JHM S protein, and three
amino acid changes relative to MHV-JHM in the subdominant
C57BL/6 CTL epitope in the same gene. The changes in the
subdominant epitope relative to MHV-JHM (RCQIFANI to
RCHIFSNL) should still permit binding to MHC class I and
antigen presentation and a CD8
 T-cell epitope (RCHIFS
NLL) at residues 587 to 595 has been identified by John Harty
and coworkers (personal communication). It is likely that the
region of the spike protein containing this epitope is function-
ally required; sequencing of multiple MHV spike genes dem-
onstrated that the hypervariable domain of S1 tolerates dele-
tions, but these deletions end at or before this epitope (34).
Furthermore, our attempts at recovering recombinant MHV-
A59 with mutations within the sequence encoding this epitope
were unsuccessful (unpublished data). To our knowledge,
there are no published studies that identify T-cell epitopes for
A/J mice for any strain of MHV.
Targeted recombination was used to select chimeric viruses
containing either the MHV-1 S gene or genes encoding all of
the MHV-1 structural proteins, on MHV-A59 and MHV-JHM
backgrounds. Growth curves with the rA59/MHV-1 chimeras
demonstrated that these recombinant viruses grew efficiently in
vitro with growth kinetics similar to those of the parental
MHV-A59 and MHV-1 viruses (Fig. 2). The maximal titers
FIG. 7. Pulmonary histopathology in mice infected with a high dose
of rA59, rA59/S33UTRMHV-1, or rA59/SMHV-1. Mice were infected
by intranasal inoculation with 100,000 PFU of rA59, rA59/
S33UTRMHV-1 (plaque isolate B), or rA59/SMHV-1 (plaque isolate C)
and sacrificed at 4 and 7 days postinfection. Lungs were removed, fixed
with buffered formalin, paraffin embedded, sectioned, and stained with
hematoxylin and eosin. (A) rA59 at day 4 postinfection. The alveolar
walls are diffusely thickened by a mononuclear cell infiltrate, which
reduces the size of alveolar lumens. This is mild interstitial pneumo-
nitis (grade 1). (B) rA59 at day 7 postinfection. The alveolar walls are
diffusely thickened by mononuclear cells. The appearance is un-
changed from day 4. This is mild interstitial pneumonitis (grade 1).
(C) r59/SMHV-1 at day 4 postinfection. The alveolar walls are thickened
by a mononuclear cell infiltrate which is slightly variable from place to
place as shown: the changes are slightly greater on the left side of the
micrograph. This is interstitial pneumonitis (grade 2). (D) r59/SMHV-1
at day 7 postinfection. The alveolar walls are thickened throughout.
Note that the changes are more severe on the right of the micrograph,
where the infiltration is greater and alveolar luminal spaces are
smaller. The figure is entirely representative. This is interstitial pneu-
monitis (grades 2 to 3). (E) rA59/S33UTRMHV-1 at day 4 postinfec-
tion. The lung is greatly altered by a heavy interstitial infiltrate of
alveolar walls, with few patent alveoli, and some of these mononu-
clear cells can be seen (as in the upper left corner). This is mod-
erate-to-severe interstitial pneumonitis (grades 3 to 4). (F) rA59/
S33UTRMHV-1 at day 7 postinfection. Shown are severe changes
with obliteration of large areas of the lung by thickened alveoalar
walls and cellular infiltration. This is severe interstitial pneumonitis
with consolidation (grade 4). All micrographs are 250. The left
panels represent day 4, and the right panels represent day 7.
9286 LEIBOWITZ ET AL. J. VIROL.
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
achieved by these chimeras were equal to or somewhat greater
than those achieved by MHV-1. Taken together, these data
suggest that the rA59/MHV-1 chimeric viruses did not have
replication defects that would preclude interpreting in vivo
findings.
Challenge studies in mice demonstrated that expression of
the MHV-1 S gene in the MHV-A59 background (rA59/
SMHV-1) increased the pneumovirulence of MHV-A59. Mice
infected with this virus developed pulmonary lesions that were
less severe than those observed with MHV-1. Compatible with
this finding, the rA59/SMHV-1 virus was much less virulent, with
an LD50 approximately 200-fold greater than that observed
with MHV-1. Chimeras containing all of the MHV-1 structural
genes on an MHV-A59 background reproduced the SARS-like
pathology observed with MHV-1 and reproducibly increased
pneumovirulence relative to the rA59/SMHV-1 virus. However,
this chimera was still considerably less virulent than MHV-1,
with an estimated LD50 50- to 100-fold greater than that of
MHV-1. A summary table depicting the results of scoring for
total inflammation along with the histology data of mice in-
fected with the low dose of viruses is shown in Table 4. Col-
lectively, these data suggest that important determinants of
pneumopathogenicity are contained within the 3 one-third of
the MHV-1 genome, but additional important virulence fac-
tors must be encoded in the genome upstream of the S gene.
Similar chimeric viruses containing MHV-1 genes in an MHV-
JHM background were completely attenuated. There are sev-
eral possible interpretations of this result: MHV-JHM could
encode upstream genes that somehow impede pneumoviru-
lence; JHM is well adapted to the CNS and does not replicate
in other organs. Indeed, the JHM background genes eliminate
the ability of a chimeric virus expressing the A59 spike protein
to induce hepatitis (28). However, in the context of A59/JHM
chimeras, the restriction to the CNS maps to the 3 third of the
genome containing the structural genes (29), perhaps different
from the observations with the MHV-1/JHM chimeras. Alter-
natively, MHV-A59 and MHV-1 genes upstream of HE may
make a contribution to pneumovirulence that is absent in the
corresponding MHV-JHM genes, or there is the trivial expla-
nation that some incompatibility between MHV-JHM and
MHV-1 genes results in “crippled” viruses. We view the latter
of these possibilities as unlikely as the replication in cell culture
of both types of rJHM/MHV-1 chimeras approximated that of
parental MHV-JHM. Currently, we cannot distinguish be-
tween the other two possibilities. The lack of neurovirulence of
these rJHM/MHV-1 viruses is consistent with previous obser-
vations that demonstrate that the JHM spike gene plays a key
role in the high neurovirulence of MHV-JHM (14, 38).
A number of genes 5 to the S gene have been shown to
contribute to MHV-A59 pathogenesis. These genes might also
contribute to the pathogenesis of the pulmonary disease ob-
served in MHV-1-infected mice. These include the ns2 gene
encoding a putative viral cyclic phosphodiesterase required for
hepatovirulence (42, 45), the ADP-ribose-1-phosphatase con-
tained within nsp3 (11), nsp14 (45), and the MHV N protein
(56). While the papain-like protease (PLP) domains of SARS-
CoV and HCoV-NL63 (13) have been demonstrated to be type
I interferon antagonists, the role of the analogous MHV PLP-2
is controversial (13) (60). A sequence comparison of MHV-1
with MHV-A59 indicates that MHV-1 and MHV-A59 Orf1a
and Orf1b are very similar, with 95.3% and 98.5% sequence
identity, respectively. There is a small region within MHV-1
nsp3 that divergences significantly from the MHV-A59 nsp3
sequence. This region does not map to one of the identified
functional domains within nsp3, leaving its functional rele-
vance unknown. This sequence difference, as well as smaller
differences in Orf1a and Orf1b, could potentially influence the
pathogenesis of MHV-1 infection.
Studies with both SARS patients (2, 36, 40, 48, 52, 59) and
the MHV-1 model studied here (9, 17) suggest that the pul-
monary lesions observed in these two infections correlate with
elevated levels of inflammatory cytokines rather than with viral
replication in the lungs. Our current work supports these ob-
servations; there was a poor correlation between the replica-
tion of the different viruses and the severity of the pulmonary
pathology. MHV-A59 replicated as well as or better than
MHV-1 and all of the rA59/MHV-1 chimeras, but failed to
induce significant pulmonary pathology (Fig. 3 and 4). This
situation is similar to that observed in the CNS disease induced
TABLE 1. Fold induction of lung cytokine and chemokine mRNAs at 36 h postinfection
Cytokine or
chemokine
Fold induction of mRNAa
MHV-1 rA59 rJHM rA59/SMHV-1 rA59/S33UTRMHV-1 rJHM/SMHV-1 rJHM/S33UTRMHV-1
M-CSF 1.52  0.13 2.21  0.65 0.72  0.10 1.04  0.21 1.77  0.07 0.95  0.06 0.76  0.16
TNF- 3.59  0.29 3.86  0.11 0.95  0.06 2.43  0.11 1.77  0.13 1.38  0.20 0.50  0.08
FGL2 2.35  0.38 1.44  0.11 0.82  0.11 1.37  0.24 1.48  0.12 1.10  0.18 0.47  0.03
IL-6 13.2  1.44 18.8  1.2 2.33  0.08 13.8  1.3 13.5 0.76 5.05 0.96 0
IFN- 26.0  0.92 7.20  2.6 1.18  0.69 16.6  3.5 12.8 2.7 3.23  1.9 0
IFN- 42  12 4.1  1.7 1.3  0.4 34  3.6 25 4.1 1.2  0.8 1.6  1.1
IFN-1 3.2  0.5 2.6  0.5 0.4  0.2 4.5  1.1 6.2 2.1 0.5  0.3 0.8  0.5
IFN-2 24  8 16  7 2.1  0.5 38  4.6 37 7.3 1.4  0.5 1.2  0.2
IFN-4 32.2  3.8 18.4  3.2 2.6  1.2 19.4  2.5 26.7 5.3 0.7  0.3 1.2  1.1
IFN-5 1.8  0.5 2.2  0.4 0.2  0.1 3.9  1.2 6.2  2.2 0 0.6  0.3
CCL2 30.4  8.6 11.4  4.2 1.04  0.36 7.18  3.6 7.13 1.4 2.51  0.70 0
CCL3 4.96  0.76 3.34  0.11 0.55  0.20 1.95  0.41 2.09  0.12 1.10  0.27 0
CCL5 3.80  0.48 5.06  1.2 1.08  0.06 2.61  0.38 3.44  0.08 1.22  0.19 0.74  0.02
CXCL2 5.17  0.53 3.68  0.64 1.38  0.43 2.10  0.54 2.50  0.64 1.38  0.12 3.39  0.22
a Results are expressed as fold induction compared to mock-infected control mice. Cytokines induced by more than 4-fold are in bold. Values of 0 are below
detectable levels.
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by MHV-JHM and MHV-A59 infection, both during the acute
encephalitic phase of disease and during the largely immuno-
logically mediated demyelinating phase of the disease. In both
phases, there is a poor correlation with virus load and pathol-
ogy (14, 39, 47). Taken together, these data suggest that the
chemokine and cytokine inflammatory response of the host to
the virus accounts for the severity of the pulmonary pathology.
The mRNAs encoding the cytokines IL-6, IFN-, IFN-,
IFN-2, and IFN-4 and the chemokine CCL2 were all
strongly induced in the lungs of mice infected with MHV-1,
rA59, or the rA59/MHV-1 chimeras and either were not in-
duced or only demonstrated moderate increases in mRNA
levels in mice infected with rJHM or the rJHM/MHV-1 chi-
meras. Thus, high levels of mRNAs for these cytokines corre-
lated well with high levels of virus replication in lung. In gen-
eral, the highest levels of cytokine expression were observed in
animals which had the most severe pulmonary pathology, that
is mice infected with MHV-1 and rA59/S33UTRMHV-1, the
mice infected with rA59/SMHV-1 generally having a somewhat
less brisk cytokine response and the mice infected with rA59
having a further muted, but still fairly robust, cytokine re-
sponse. The minimal degree of pulmonary inflammation ob-
served in rA59-infected mice is somewhat surprising in light of
their cytokine responses. At this time, we do not have a good
explanation for this observation. Significant increases in serum
levels of the proinflammatory cytokines IFN-, IL-1, IL-6,
and IL-12 correlated with disease severity, as reported previ-
ously in an experimental model of SARS (9) and in SARS
patients (1, 49).
The pulmonary lesions observed in SARS are thought in
part to be mediated by a robust increase in proinflammatory
cytokines in response to viral replication in the lungs. A recent
study comparing two mouse-adapted strains of the SARS coro-
navirus (SARS-CoV) and the Urbani strain, which does not
produce significant pathology in young mice, reported elevated
levels of pulmonary IL-6, CCL3, IFN-, CCL2, and CCL5 at 3
days postinfection, with the increases in CCL3 and IL-6 cor-
relating with increasing pneumovirulence in the mouse (8).
Although we determined relative cytokine mRNA levels rather
than determine the cytokine levels themselves, the cytokine
responses we observed with MHV-1 are similar to those re-
ported by Day et al. (8), particularly if we look at our data at
4 days postinfection (Table 2), where the correlation of IL-6
and CCL3 mRNA levels with lung pathology is most apparent.
In a study utilizing aged mice, which develop pulmonary dis-
ease in response to infection with the Urbani strain of SARS-
CoV, Chen et al. (4) demonstrated both an early wave of
cytokines (TNF- and IL-6) and chemokines (CXCL10, CCL2,
CCL3, and CCL5) at 2 days postinfection and a late wave of
cytokines (TNF-, IL-6, IFN-, IL-2, and IL-5) and chemo-
kines (CXCL9, CXCL10, CCL2, CCL3, and CCL5) and their
receptors (CXCR3, CCR2, and CCR5) at 7 days postinfection,
when pulmonary pathology had developed. Thus, in both the
MHV-1 model of SARS and in several mouse models of
TABLE 2. Kinetics of cytokine/chemokine induction
by virus infection
Cytokine or chemokine
and virus
Fold induction at postinfection timea:
36 h Day 4 Day 7
IFN-
MHV-1 26.0  0.92 48.3  7.2 62.7  8.7
rA59 7.20  2.6 4.1  1.2 1.4  2.1
rJHM 1.18  0.69 0 0
rA59/SMHV-1 16.6  3.5 12.2  4.2 4.3  1.7
rJHM/SMHV-1 3.23  1.9 1.1  0.4 1.0  1.1
rA59/S33UTRMHV-1 12.8  2.7 28.7  4.2 47.6  11.4
rJHM/S33UTRMHV-1 0 0 0
TNF-
MHV-1 3.59  0.29 6.7  3.2 11.2  2.1
rA59 3.86  0.11 2.1  0.7 1.6  0.8
rJHM 0.95  0.06 1.1  0.4 0
rA59/SMHV-1 2.43  0.11 1.7  0.4 1.2  0.1
rJHM/SMHV-1 1.38  0.20 0 1.1  0.15
rA59/S33UTRMHV-1 1.77  0.13 6.3  2.1 8.4  2.7
rJHM/S33UTRMHV-1 0.50  0.08 1.61  0.18 0.92  0.17
IL-6
MHV-1 13.2  1.44 17.7  2.1 8.7  1.6
rA59 18.8  1.2 14.2  2.1 3.7  1.6
rJHM 2.33  0.08 1.3  0.9 1.4  0.4
rA59/SMHV-1 13.8  1.3 11.2  1.7 6.1  2.3
rJHM/SMHV-1 5.05  0.96 2.2  0.9 1.9  0.7
rA59/S33UTRMHV-1 13.5  0.76 21.4  3.2 32.5  7.2
rJHM/S33UTRMHV-1 0 1.1  0.4 0
FGL2
MHV-1 2.35  0.38 6.3  1.7 8.1  2.2
rA59 1.44  0.11 1.9  0.8 1.3  0.25
rJHM 0.82  0.11 0.79  0.20 0
rA59/SMHV-1 1.37  0.24 1.32  0.36 1.71  0.4
rJHM/SMHV-1 1.10  0.18 1.03  0.21 1.1  0.2
rA59/S33UTRMHV-1 1.48  0.12 6.7  1.1 12.2  4.4
rJHM/S33UTRMHV-1 0.47  0.03 2.8  0.4 2.9  0.5
CCL2
MHV-1 30.4  8.6 24.8  4.3 21.2  7.1
rA59 11.4  4.2 6.9  1.8 5.2  2.1
rJHM 1.04  0.36 1.7  0.45 1.5  0.22
rA59/SMHV-1 7.18  3.6 8.2  4.3 5.1  0.7
rJHM/SMHV-1 2.51  0.70 2.9  1 2.4  0.4
rA59/S33UTRMHV-1 7.13  1.4 11.2  1.7 4.5  1.3
rJHM/S33UTRMHV-1 0 0 0
CCL3
MHV-1 4.96  0.76 7.2  2.3 8.4  1.7
rA59 3.34  0.11 1.8  0.5 1.4  0.2
rJHM 0.55  0.20 0.6  0.4 1.1  0.2
rA59/SMHV-1 1.95  0.41 3.2  0.8 4.1  0.2
rJHM/SMHV-1 1.10  0.27 0.7  0.4 0.85  0.2
rA59/S33UTRMHV-1 2.09  0.12 6.4  1.7 7.7  1.7
rJHM/S33UTRMHV-1 0 0 0
a Results are expressed as fold induction compared to mock-infected control
mice. Values of 0 are below detectable levels.
TABLE 3. Serum cytokine or chemokine levels at
2 days postinfection
Cytokine or
chemokine
Serum cytokine or chemokine level (pg/ml)
Uninfected MHV-1 rA59/SMHV-1 rA59/S33UTRMHV-1
IL-10 23.5  6 204.8  12 42.3  12 394  18
IL-6 48.1  3.6 836  9 38.6  12 1184  64
IL-12p70 136  21 483  28 184  18 528  30
IFN- 12  2 736  62 21  6 596  81
TNF- 18  4 184  22 32  5 204  21
CCL2 104  7 6140  280 186  9 5470  30
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SARS-CoV infection, the elaboration of these proinflamma-
tory molecules correlates with pulmonary pathology. The cy-
tokine and chemokine responses of mice to MHV-1 infection
(9) presented here and SARS-CoV infections of mice (4, 8)
largely mirror those of patients infected during the 2002–2003
SARS outbreak (2, 5, 40, 48, 52, 59), with elevated levels of
proinflammatory cytokines and chemokines, particularly
IFN-, IL-6, and IFN--inducible protein 10 (IP-10; CXCL10).
In a previous report (9), the intrapulmonary cell infiltrates
seen in MHV-1-infected A/J mice were predominantly macro-
phages, with modest numbers of CD3
 T cells and neutrophils,
similar to that seen in human SARS. Furthermore, by immu-
noelectron microscopy we demonstrated that MHV-1 was pri-
marily localized in the intrapulmonary macrophages, similar to
what has been reported with SARS patients (9).
Given the similarity of the pathology and the cytokine and
chemokine responses of MHV-1-infected mice to human
SARS and the advantages of an agent that only requires
biosafety level 2 (BSL-2) containment, we believe that this
model system has great potential to further the study of
SARS pathogenesis, keeping in mind that it is likely that
there will also be some differences since MHV-1 lacks the
unique accessory genes found in SARS-CoV. Further stud-
ies are now under way in our laboratories to examine the
role of various coronavirus genes in the pathogenesis of
severe pulmonary infections, which hopefully will lead to
new therapies to prevent the morbidity and mortality asso-
ciated with these pathogens.
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